Thursday, 3 October 2013

Edoxaban – HOTSUKAI VTE STUDY Results at ESC-13- Well differentiated and should carve its niche in VTE patients with PE/Renal impairment - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28657/Edoxaban-%E2%80%93-HOTSUKAI-VTE-STUDY-Results-at-ESC-13--Well-differentiated-and-should-carve-its-niche-in-VTE-patients-with-PE/Renal-impairment-/

On 1st Sep, at ESC, Daiichi-Sankyo presented positive results from the PhIII HOKUSAI-VTE study on Edoxaban in VTE (Venous thromboembolism) treatment. Edoxaban demonstrated non-inferiority in terms of efficacy and superiority in terms of safety compared to warfarin in the trial. The results are on the same lines as Eliquis and better than Xarelto and Pradaxa. Based on this data and subgroup analysis, we believe Edoxaban would be preferred primarily in those patients who present with a Pulmonary embolism (with or without DVT) and also those with renal impairment. We expect the market size for VTE treatment to be.....................
HOKUSAI –VTE Implications for ENGAGE-AF.........................

SymBio pharma - TREAKISYM Label Expansion - Rigosertib’s Potential in MDS market - Cash to In-license More - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28664/SymBio-pharma---TREAKISYM-Label-Expansion---Rigosertib%E2%80%99s-Potential-in-MDS-market---Cash-to-In-license-More/

SymBio (4582) licensed Onconova’s Rigosertib (SyB L-1101, PhI, RRMDS, Dual inhibitor of PI-3 and PL-1 Kinase Inhibitor) and gained Japan/Korea rights in 2011. Onconova Therapeutics (ONTX) debut in NASDAQ has been very encouraging and should percolate into SymBio especially in light of the upcoming PhIII data in US of Rigosertib IV (Rig. IV) in RRMDS by YE13. Disappointing guidance of TREAKISYM (bendamustine hydrochloride, L, rrNHL, MCL) sales for FY13 (¥1,563m, lowered down by ~¥365m) hit the stock, but future potential of its product portfolio remains intact with... For more detail please read our report on SymBio released on 3rd Sept. 2013, titled, "TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More!"

Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches - Maturing Pipeline - Long Term Gain - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28665/-Celgene-(CELG)---Label-Expansion-of-Marketed-Product-and-Newly-Drug-launches---Maturing-Pipeline---Long-Term-Gain/

CELG’s Maturing pipeline through its own proprietary compounds and acquisition/in-licensing should keep the momentum positively in coming years. New launches – POMALYST (L, Pomalidomide, RRMM), Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013) should sustain the growth for long term. CELG has recently raised $1.5b in senior notes strengthening its balance sheet and continues it buyback plans ($3b announced in June 2013). We expect ... For more detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain".



Onconova Therapeutics (ONTX) -Near-Term Catalysts = Upside Still! - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28660/Onconova-Therapeutics-(ONTX)--Near-Term-Catalysts-=-Upside-Still!/

Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: 5.9m share offering @ $15 July 25, 2013) has been impressive (30% up since IPO), raising the inevitable question – Is this the upper limit or is there still room for upside? Estybon is targeting a niche patient pool, where unmet medical needs remain due to lack of effective treatment or no approved therapies. Rig. IV showed median overall survival of 35 weeks in four early-stage PhI/II trials in pts with 2nd-line Higher Risk MDS vs. less than six months offered by current standard of care (as per historic peer-reviewed published reports). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON 01910.Na, PhIII, PI3K-PLK inhibitor, partnered with Baxter for EU rights and SymBio pharma for Japan & Korean rights) is ... For more detail please read our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"

Ambit Biosciences (AMBI) - Early Approval of Quizartinib in RR-AML = A Risk Worth Taking - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28661/Ambit-Biosciences-(AMBI)---Early-Approval-of-Quizartinib-in-RR-AML-=-A-Risk-Worth-Taking/

Regaining WW rights to Quizartinib (PhII/III, a selective oral potent FLT3, FMS like tyrosine kinase-3 inhibitor for acute myeloid leukemia, AML) from Astellas in 2013 armed AMBI to tap the unmet need in refractory/ relapsed AML (RR AML) and related hematological disorders. In the PhIIb study pts, FLT3 positive AML patients relapsed/refractory to one or more prior therapies treated with quizartinib achieved CRc rates of 46% vs.3-4% seen with other tyrosine kinase inhibitors. FDA is reviewing the data, new endpoints and is likely to announce its decision by Nov 2013. The drug has a fast track in orphan status and the company is on track to start the PhIII trial in 2014 in rrAML irrespective of the FDA’s decision. Even if the drug does not get approved in ... For more detail please read our report on Ambit released on 30th August 2013, titled, "Early Approval of Quizartinib in RR-AML = A Risk Worth Taking".

Tuesday, 17 September 2013

Big Data and Telecom Analytics Market: Business Case, Market Analysis & Forecasts 2014 - 2019 - Reports Corner

For complete information about the report, please visit our website


Big Data refers to a massive volume of both structured and unstructured data that is so large that it is difficult to process using traditional database and software techniques.  While the presence of such datasets is not something new, the past few years have witnessed immense commercial investments in solutions that address the processing and analysis of Big Data.
 
Big Data opens a vast array of applications and opportunities in multiple vertical sectors including, but not limited to, retail and hospitality, media, utilities, financial services, healthcare and pharmaceutical, telecommunications, government, homeland security, and the emerging industrial Internet vertical.
 
With access to vast amounts of data sets, telecommunications companies are emerging as major proponents of the Big Data movement. Big Data technologies, and in particular their analytics abilities, offer a multitude of benefits to telecom companies including improved subscriber experience, building and maintaining smarter networks, reducing churn, and generation of new revenue streams. 
 
Mind commerce, thus expects the Big Data driven telecom analytics market to grow at a CAGR of nearly 50% between 2014 and 2019. By the end of 2019, the market will eventually account for $5.4 Billion in annual revenue.
 
This report provides an in-depth assessment of the global Big Data and telecom analytics markets, including a study of the business case, application use cases, vendor landscape, value chain analysis, case studies and a quantitative assessment of the industry from 2013 to 2019.
 
Topics covered in the report include: 
• The Business Case for Big Data:  An assessment of the business case, growth drivers and barriers for Big Data 
• Big Data Technology:  A review of the underlying technologies that resolve big data complexities
• Big Data Use Cases:  A review of investments sectors and specific use cases for the Big Data market  
• The Big Data Value Chain:  An analysis of the value chain of Big Data and the major players involved within it
• Big Data in Telco Analytics:  How telecom can utilize Big Data technology to reduce churn, optimize their networks, reduce risks and create new revenue streams
• Telco Case Studies:  Case Studies of two major wireless telecom capitalizing on Big Data to reduce churn and improve revenue
• Vendor Assessment & Key Player Profiles:  An assessment of the vendor landscape for leading players within the Big Data market
• Market Analysis and Forecasts:  A global and regional assessment of the market size and forecasts for the Big Data market from 2014 to 2019
Key Findings:
• Big Data opens a vast array of applications and opportunities in multiple vertical sectors including, but not limited to, retail and hospitality, media, utilities, financial services, healthcare and pharmaceutical, telecommunications, government, homeland security, and the emerging industrial Internet vertical.
• Mind Commerce has determined that IBM leads the Big Data market in terms of current investments (from a vendor perspective), with estimated revenue for $1.3 Billion in 2012 for its Big Data services, software and hardware sale
• Despite challenges such as the lack of clear big data strategies, security concerns and the need for workforce re-skilling, the growth potential of Big Data is unprecedented. Mind Commerce estimates that global spending on Big Data will grow at a CAGR of 48% between 2014 and 2019. Big Data revenues will reach $135 Billion by the end of 2019
• Big Data technologies, and in particular their analytics abilities offer a multitude of benefits to telecom including improving subscriber experience, building & maintaining smarter networks, reducing churn and even the generation of new revenue streams
• The Big Data driven telecom analytics market to grow at a CAGR of nearly 50% between 2014 and 2019. By the end of 2019, the market will eventually account for $5.4 Billion in annual revenue.
Target Audience:
• Investment Firms
• Media Companies
• Utilities Companies
• Financial Institutions
• Application Developers
• Government Organizations
• Retail & Hospitality Companies
• Other Vertical Industry Players
• Analytics and Data Reporting Companies
• Healthcare Service Providers & Institutions
• Fixed and Mobile Telecom service providers
• Big Data Technology/Solution (Infrastructure, Software, Service) Vendors

Australia Solar Power Sector Opportunity Analysis - Reports Corner

For complete information about the report, please visit our website


https://www.reportscorner.com/reports/27512/Australia-Solar-Power-Sector-Opportunity-Analysis/



As Australia is moving towards increased solar power generation, the installed capacity of solar modules has shown considerable growth in the recent years. The use of solar energy for power generation had started way back in 1992 in the country with a few pilot projects and an installed capacity of 7.3 MW. With Australia’s power generation dominated by fossil fuels and a lack of clear solar energy policies and growth framework, the installed capacity could not grow more than 2 to 5 MW per year till 2001. Also, this period saw a growth in hydro and wind power production systems indicating the government’s focus on the other known and technologically available sources of clean energy. Post 2001, the installed capacity addition was in the range of 5 to 12 MW till 2007 on a per year basis. It was only in 2007 when solar power production gained weight and the installed capacity started growing by a larger margin. 
The last couple of years (2011 & 2012) have truly been the solar years for Australia with solar announcing its arrival in a grand manner. More than 1.6 GW was added in last two years which have given solar power development the required momentum. This was achieved through a change in policies and a greater shift of focus of the government from other renewable sources to solar energy. Solar PV in Australia is divided into four sub markets namely, Off-grid domestic, off-grid non-domestic, grid-connected distributed and grid-connected centralized. These four sub markets signify the distribution of the installed capacity in the country. 
Solar PV technology is bound to play a larger role in the electricity production sector of Australia which will certainly be augmented by the increasing investments and positively shaping policies. The government is keen on exploiting all its energy sources and solar being one of the most abundant has taken priority over others. The technology is entering its advanced stage and Australia looks set to embrace the solar energy giving it a bigger share in power generation in the coming years.

“Australia Solar Power Sector Opportunity Analysis” discusses following key issues related to solar power development in Australia:
• Australia Power Sector Overview
• Solar Radiation & Potential
• Grid Connected & Off Grid Solar Capacity
• Domestic & Commercial Solar Capacity
• Feed in Tariff Structure by State
• Photovoltaic Module Manufacturing
• Development of Solar Cities
• Regulatory & Policy Initiatives
• Competitive Landscape